Lucira Health, Inc. (LHDX) News

Lucira Health, Inc. (LHDX): $2.01

0.05 (+2.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LHDX News Items

LHDX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LHDX News Highlights

  • For LHDX, its 30 day story count is now at 4.
  • Over the past 5 days, the trend for LHDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • HTGC, LOAN and SIVB are the most mentioned tickers in articles about LHDX.

Latest LHDX News From Around the Web

Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.

Lucira Health Shares Fall After Announcing Debt Facility Of $80M

Lucira Health Inc (NASDAQ: LHDX) has entered into a debt facility of up to million with Hercules Capital and Silicon Valley Bank. Under the term loan, Lucira received the first tranche of $30 million at closing. The Company will receive the second tranche of $20 million upon achieving certain milestones between September 1, 2022, and March 31, 2023. The third tranche of $15 million will be available before June 15, 2023, also contingent on certain milestones, while the fourth tranche of $15 mill

Yahoo | February 8, 2022

Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank

EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing will provide Lucira l

Yahoo | February 8, 2022

The past year for Lucira Health (NASDAQ:LHDX) investors has not been profitable

As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and...

Yahoo | February 7, 2022

Lucira™ Health Commits 2 Million At-Home Molecular COVID-19 Test Kits on Amazon

Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced more than two million Lucira™ Check-It COVID-19 tests, a rapid at-home test with PCR-quality accuracy, are available on Amazon.com. Lucira's tests are available with 1-2 day Prime delivery nationwide.

Yahoo | February 3, 2022

Roche to offer 'tens of millions' of at-home Covid tests by end of month

The rollout comes amid long lines at testing sites and President Joe Biden's promise to increase the number of tests available.

Yahoo | January 11, 2022

Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test Now Available in the Optum Store

Lucira's COVID-19 test is the only EUA authorized rapid at-home self-test that delivers PCR accuracy and early detectability in a single-use test kit with results in 30 minutes Availability in the Optum Store expands access to this unique testing option amidst a surge of US COVID-19 cases caused by the Omicron variant Lucira's test uniquely offers PCR accuracy and early detection without the 24 hour+ wait for results EMERYVILLE, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Luc

Yahoo | January 11, 2022

Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021. Preliminary, unaudited revenue for the fourth quarter 2021 is expected to be between $58 million and $60 million, reflecting growth of approximately 300% over the unaudite

Yahoo | January 10, 2022

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 31, 2021 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or "the Company") (NASDAQ:LHDX) for violations of the securities laws.

Yahoo | January 1, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX

Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | December 30, 2021

Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022

Lucira is the only EUA authorized at-home self-test kit that delivers PCR-quality accuracy and early detectability in a single-use test kit with results in 30 minutesCo-Defend and Co-Protect are leading providers of customized health & safety solutions, and testing & advisory services to Entertainment, Federal, State, and Local governments, Fortune 500 companies, and professional sports teams and leagues EMERYVILLE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq

Yahoo | December 29, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4382 seconds.